Navigation Links
Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

;All manufacturing costs for KRYSTEXXA after FDA approval are recorded as inventory as opposed to research and development prior to approval.

Selling, general and administrative expenses increased $15.0 million to $22.3 million for the three months ended September 30, 2011, from $7.3 million for the three months ended September 30, 2010.  The higher expenses for the three months ended September 30, 2011 were primarily due to increased selling and marketing expenses associated with the full commercial launch of KRYSTEXXA.  

Interest expense on the Company's convertible notes was $3.4 million for the three months ended September 30, 2011.

Conference Call and WebcastThe Company will host a live conference call and webcast beginning at 9:00 a.m. Eastern Time on November 3, 2011 to discuss these results and to answer questions.  To participate by telephone, please dial:Domestic:

866-393-9370 International:

706-679-1207 Conference ID:

17722127The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com.  Please log on to Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary. A telephone replay will be available from 12:00 p.m. Eastern Time on November 3, 2011 through 12:00 a.m. Eastern Time on November 17, 2011 by dialing:Domestic:

855-859-2056 or 800-585-8367 International:

404-537-3406 Conference ID:

17722127ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Moun
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
2. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
3. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
4. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
5. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
6. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
7. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
8. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
9. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
10. Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
11. Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Research ... the addition of the "Global Gynecological ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... classified into wide categories based on their ... treatment of different gynecological conditions that affect ...
(Date:9/19/2014)... CHICAGO , Sept. 19, 2014  4WEB Medical ... of 3D-printed foot and ankle osteotomy implants on ... and Ankle Society annual meeting in Chicago ... for all of a surgeon,s osteotomy needs with 74 size ... wedge systems had smaller offerings of only 15 to 18 ...
(Date:9/19/2014)... , Sept. 19, 2014 UBM Medica US ... leading online community to help oncologists and other clinicians ... regarding the use of targeted therapies and immunotherapies, discusses ... and treatment.  Every September, Blood ... to raise awareness about blood cancers—helping to increase survival ...
Breaking Medicine Technology:Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 34WEB Medical Unveils 3D-Printed Osteotomy Truss System 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4
... Journal of Medicine Study Questions Value of Knee ... new study,questioning the usefulness of arthroscopic surgery for ... physical therapy as an,effective non-surgical option, according to ... published in the September 11 issue of,the New ...
... Vanda,Pharmaceuticals Inc. (Nasdaq: VNDA ), a biopharmaceutical ... product candidates,for central nervous system disorders, reported today ... 2008 and discuss the iloperidone non-approvable action,letter that ... Vanda presented arguments to support its belief that ...
Cached Medicine Technology:New Research Shows Physical Therapy as Effective as Arthroscopic Knee Surgery 2New Research Shows Physical Therapy as Effective as Arthroscopic Knee Surgery 3Vanda Pharmaceuticals Provides Update on Iloperidone 2Vanda Pharmaceuticals Provides Update on Iloperidone 3
(Date:9/21/2014)... Colorado (PRWEB) September 21, 2014 High ... ten teams of disabled and able-bodied athletes rafted the ... completed a ropes course in pursuit of outdoor adventure. ... from national non-profit World T.E.A.M. Sports, disabilities proved to ... who successfully completed the three stage event. , Each ...
(Date:9/21/2014)... 2014 “Cluster headaches are sometimes called ... difficult to resolve,” said Steve Young of Ew Publishing; ... a pain that is more intense.” , “It should ... headaches, or migraines, that medical research is pointing to ... he added. , Serotonin (5-HT, 5-hydroxytryptamine) is a ubiquitous ...
(Date:9/21/2014)... Faculty and staff at Garrison Forest School ... Owings Mills, Md., kicked off the academic year by taking ... is the first independent school to receive the bands— which ... sleep patterns— as part of a pilot program with ... specialty chain. The Vivofit bands are just one tool in ...
(Date:9/21/2014)... Top10BestSEOHosting.com, a leading review website, ... GreenGeeks are the most recommended hosting suppliers for ... quality hosting products. , “Don’t waste your ... recommend two great hosting companies to you,” the ... iPage and GreenGeeks are the most recommended suppliers ...
(Date:9/20/2014)... Las Vegas, NV (PRWEB) September 21, 2014 ... created by Dr. Kenneth Pullman that is helping thousands ... reverse their diabetes symptoms without shots, pills, or prescriptions ... investigative review. , “There are currently tens of ... with both Type 1 and Type 2 diabetes, and ...
Breaking Medicine News(10 mins):Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 3Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Garrison Forest School Leader in Independent School Wellness Programs 2Health News:Leading Review Website Top10BestSEOHosting.com Unveils The Best Hosting Suppliers In September 2Health News:Diabetes Protocol: Review Exposes Kenneth Pullman’s Breakthrough Discovery About Diabetes Management 2
... report that mother to be who are obese and ... of their unborn babies., ,Researchers examined the possible ... // - primary caesarean delivery, pre-term birth and low ... J. Rosenberg of Medical Health and Research Association (MHRA), ...
... reported in the latest issue of American Journal of ... Infection can cause significant changes in the brain structures ... learning new things, problem solving, paying attention to something ... the conditions happen simultaneously., ,Methamphetamine abuse is linked ...
... that can extend the lifespan of mice by as much as ... premature aging around 3 to 4 weeks of age and die ... span of 2 years. This has indeed opened up new avenues ... brain and kidney in some animal species, which then leaks into ...
... edition of The Lancet had found the drug artesunate ... common drug quinine., ,Quinine is the only drug ... Africa, South America, and most of Asia. But even ... mortality from severe malaria remains high. Intravenous artesunate is ...
... Lucknow, Aug 26 . Japanese encephalitis deaths continue to rise ... 220 in less than a month. //, ,Dr.T.N.Dhole from ... Medical Sciences blamed "official apathy" for the unabated spread ... Uttar Pradesh for nearly three decades., ,Encephalitis is a ...
... that all the efforts to curb he disease of sleeping ... reported in this week’s issue of The Lancet., ,The ... Uganda began in 1998 as a result of the movement ... to spread. Interventions to control the disease were put in ...
Cached Medicine News:Health News:Obesity, diabetes in pregnant women affects babies 2Health News:Changes In Brain Structure From Methamphetamine Abuse And HIV Infection 2Health News:Encephalitis Deaths Cross 220 in Uttar Pradesh 2
Double ended with 0.5mm x 10mm and 1.0mm x 15mm blades; both blades gently curved; round serrated handle, In Titanium....
0.6mm Tip x10mm Shaft, Straight Shaft, 90 Degree Hook at Tip; overall length 120mm; in Titianium....
... Catheter is indicated for balloon ... of a coronary artery or ... purpose of improving myocardial perfusion. ... also designed to provide distal ...
16mm from Mid-screw to Tips, blunt tips; overall length 110mm; Stainless Steel...
Medicine Products: